Fibrolamellar Hepatocellular Carcinoma and Noncirrhotic Hyperammonemic Encephalopathy

Fibrolamellar hepatocarcinoma is an infrequent liver tumor, currently considered to be a variant different from hepatocarcinoma. The differences lie in genomic alterations, a greater prevalence of fibrolamellar hepatocarcinoma in young patients, and its lack of association with underlying liver dise...

Descripción completa

Detalles Bibliográficos
Autores Principales: Suarez, Oscar, Pérez, María, Garzón Olarte, Martín Alonso, Daza, Rodrigo, Hernandez, Geovanny, Salinas, Carolina, Ceballos, Jorge, De Leon, Enrique P., Mugnier, Jacqueline, Beltrán, Oscar, Varón, Adriana
Formato: Tesis de maestría (Master Thesis)
Lenguaje:Español (Spanish)
Publicado: Universidad del Rosario 2018
Materias:
Acceso en línea:http://repository.urosario.edu.co/handle/10336/18871
id ir-10336-18871
recordtype dspace
institution EdocUR - Universidad del Rosario
collection DSpace
language Español (Spanish)
topic Fibrolamellar hepatocellular carcinoma
Noncirrhotic hyperammonemic encephalopathy
Enfermedades
Hepatocarcinoma fibrolamelar
Enfermedades hepáticas
spellingShingle Fibrolamellar hepatocellular carcinoma
Noncirrhotic hyperammonemic encephalopathy
Enfermedades
Hepatocarcinoma fibrolamelar
Enfermedades hepáticas
Suarez, Oscar
Pérez, María
Garzón Olarte, Martín Alonso
Daza, Rodrigo
Hernandez, Geovanny
Salinas, Carolina
Ceballos, Jorge
De Leon, Enrique P.
Mugnier, Jacqueline
Beltrán, Oscar
Varón, Adriana
Fibrolamellar Hepatocellular Carcinoma and Noncirrhotic Hyperammonemic Encephalopathy
description Fibrolamellar hepatocarcinoma is an infrequent liver tumor, currently considered to be a variant different from hepatocarcinoma. The differences lie in genomic alterations, a greater prevalence of fibrolamellar hepatocarcinoma in young patients, and its lack of association with underlying liver disease. The clinical presentation is unspecific, with symptoms ranging from abdominal pain, malaise, and weight loss to atypical manifestation which include hyperammonemic encephalopathy. We present the case of a 33-year-old woman with no prior medical history who presented with a coma and a diagnosis of inoperable fibrolamellar hepatocarcinoma requiring a cadaver donor transplant. While she was on the waiting list, she received hemofiltration and ammonium benzoate treatment, with progressive improvement in her state of consciousness.
author2 Garzón Olarte, Martín Alonso
author_facet Garzón Olarte, Martín Alonso
Suarez, Oscar
Pérez, María
Garzón Olarte, Martín Alonso
Daza, Rodrigo
Hernandez, Geovanny
Salinas, Carolina
Ceballos, Jorge
De Leon, Enrique P.
Mugnier, Jacqueline
Beltrán, Oscar
Varón, Adriana
format Tesis de maestría (Master Thesis)
author Suarez, Oscar
Pérez, María
Garzón Olarte, Martín Alonso
Daza, Rodrigo
Hernandez, Geovanny
Salinas, Carolina
Ceballos, Jorge
De Leon, Enrique P.
Mugnier, Jacqueline
Beltrán, Oscar
Varón, Adriana
author_sort Suarez, Oscar
title Fibrolamellar Hepatocellular Carcinoma and Noncirrhotic Hyperammonemic Encephalopathy
title_short Fibrolamellar Hepatocellular Carcinoma and Noncirrhotic Hyperammonemic Encephalopathy
title_full Fibrolamellar Hepatocellular Carcinoma and Noncirrhotic Hyperammonemic Encephalopathy
title_fullStr Fibrolamellar Hepatocellular Carcinoma and Noncirrhotic Hyperammonemic Encephalopathy
title_full_unstemmed Fibrolamellar Hepatocellular Carcinoma and Noncirrhotic Hyperammonemic Encephalopathy
title_sort fibrolamellar hepatocellular carcinoma and noncirrhotic hyperammonemic encephalopathy
publisher Universidad del Rosario
publishDate 2018
url http://repository.urosario.edu.co/handle/10336/18871
_version_ 1694382381091258368
spelling ir-10336-188712021-03-01T19:22:56Z Fibrolamellar Hepatocellular Carcinoma and Noncirrhotic Hyperammonemic Encephalopathy Suarez, Oscar Pérez, María Garzón Olarte, Martín Alonso Daza, Rodrigo Hernandez, Geovanny Salinas, Carolina Ceballos, Jorge De Leon, Enrique P. Mugnier, Jacqueline Beltrán, Oscar Varón, Adriana Garzón Olarte, Martín Alonso Pérez, María Fibrolamellar hepatocellular carcinoma Noncirrhotic hyperammonemic encephalopathy Enfermedades Hepatocarcinoma fibrolamelar Enfermedades hepáticas Fibrolamellar hepatocarcinoma is an infrequent liver tumor, currently considered to be a variant different from hepatocarcinoma. The differences lie in genomic alterations, a greater prevalence of fibrolamellar hepatocarcinoma in young patients, and its lack of association with underlying liver disease. The clinical presentation is unspecific, with symptoms ranging from abdominal pain, malaise, and weight loss to atypical manifestation which include hyperammonemic encephalopathy. We present the case of a 33-year-old woman with no prior medical history who presented with a coma and a diagnosis of inoperable fibrolamellar hepatocarcinoma requiring a cadaver donor transplant. While she was on the waiting list, she received hemofiltration and ammonium benzoate treatment, with progressive improvement in her state of consciousness. UNIVERSIDAD DEL ROSARIO 2018-12-03 2019-01-11T22:07:53Z info:eu-repo/semantics/masterThesis info:eu-repo/semantics/acceptedVersion http://repository.urosario.edu.co/handle/10336/18871 spa Atribución-NoComercial-SinDerivadas 2.5 Colombia http://creativecommons.org/licenses/by-nc-nd/2.5/co/ info:eu-repo/semantics/openAccess application/pdf Universidad del Rosario Especialización en Gastroenterología Facultad de Medicina reponame:Repositorio Institucional EdocUR instname:Universidad del Rosario H.A.Edmondson,“Differentialdiagnosisoftumorsandtumorlikelesionsofliverininfancyandchildhood,”A.M.A.American JournalofDiseasesofChildren,vol.91,no.2,pp.168–186,1956. V.Maniaci,B.R.Davidson,K.Rollesetal.,“Fibrolamellarhepatocellularcarcinoma-Prolongedsurvivalwithmultimodality therapy,”European Journal of Surgical Oncology, vol. 35,no. 6, pp.617–621,2009. M.Torbenson,“FibrolamellarCarcinoma:2012Update,”Scientifica,vol.2012,ArticleID743790,15pages,2012. E.J.GrossmanandJ.M.Millis,“Livertransplantationfornonhepatocellularcarcinomamalignancy:indications,limitations, andanalysisofthecurrentliterature,”LiverTransplantation,vol. 16,no.8,pp.930–942,2010. V. Paradis, “Histopathology of hepatocellular carcinoma,” in Multidisciplinary Treatment of Hepatocellular Carcinoma, vol. 190 of Recent Results in Cancer Research, pp. 21–32, Springer, Berlin,Germany,2013. G. M. Fonseca, A. D. Varella, F. F. Coelho, E. S. Abe, R. B. Dumarco, and P. Herman, “Downstaging and resection after neoadjuvant therapyfor fibrolamellar hepatocellularcarcinoma,”WorldJournalofGastrointestinalSurgery,vol.6,no.6, p.107,2014. D.Ganeshan,J.Szklaruk,V.Kundra,A.Kaseb,A.Rashid,and K. Elsayes, “Imaging features of fibrolamellar hepatocellular carcinoma,”AmericanJournalofRoentgenology,vol.202,no.3, pp.544–552,2014. T.Eggert,K.A.McGlynn,A.Duffy,M.P.Manns,T.F.Greten, andS.F.Altekruse,“Fibrolamellarhepatocellularcarcinomain theUSA,2000–2010:adetailedreportonfrequency,treatment andoutcomebasedonthesurveillance,epidemiology,andend Results database,” United European Gastroenterology Journal, vol.1,no.5,pp.351–357,2013. H.Cornella,C.Alsinet,S.Sayolsetal.,“Uniquegenomicprofile of fibrolamellar hepatocellular carcinoma,” Gastroenterology, vol.148,no.4,pp.806–818.e10,2015. G. G. Malouf, S. Job, V. Paradis et al., “Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrinesignature,”Hepatology,vol.59,no.6,pp.2228–2237, 2014. T. Pawlik and K. Lafaro, “Fibrolamellar hepatocellular carcinoma: current clinical perspectives,” Journal of Hepatocellular Carcinoma,p.151. T. Kanai, T. Takabayashi, Y. Kawano, S. Kuramochi, and N. Miyazawa,“Acaseofpostoperativerecurrenceoffibrolamellar hepatocellular carcinoma with increased vitamin B12 binding capacityinayoungJapanesefemale,”JapaneseJournalofClinical Oncology,vol.34,no.6,pp.346–351,2004. S. K. Asrani and N. F. Larusso, “Fibrolamellar hepatocellular carcinoma presenting with budd-chiari syndrome, right atrial thrombus, and pulmonary emboli,” Hepatology, vol. 55, no. 3, pp.977-978,2012. J.Lloreta,C.Vadell,X.Fabregat,andS.Serrano,“Fibrolamellar hepatictumorwithneurosecretoryfeaturesandsystemicdepositionofAAamyloid,”UltrastructuralPathology,vol.18,no.1-2, pp.287–292,1994. J. A. Espinosa, A. Merlo, M.-O. Arafeh, and G. Munene, “An unusualcaseofjaundice:Biliarytumorthrombusinfibrolamellar hepatocellular carcinoma,” International Journal of Surgery CaseReports,vol.36,pp.50–54,2017. K. M. Tezer, B. Yalc ¸´ın, N. B¨ uy¨ukpamukc¸u, G. Kale, and M. B¨uy¨ukpamukc¸u,“Fibrolamellarhepatocellularcarcinomawith skeletalmetastases,”PediatricHematologyandOncology,vol.18, no.4,pp.273–278,2001. N.A.Villa,R.Pannala,D.O.Faigeletal.,“Metastaticfibrolamellar hepatocellular carcinoma to the pancreas,” Case Reports in Gastroenterology,vol.9,pp.266–271,2015. S.H.Ciurea,E.Matei,C.S.Stanescuetal.etal.,“Fibrolamellar hepatocellularcarcinomawithovarianmetastasis-anunusual presentation.Rom,”JournalofMorphologyandEmbryology,vol. 58,pp.187-92,2017. O.Soreide,A.Czemiak,H.Bradpiece,S.Bloom,andL.Blumgart,“Characteristicsoffibrolamellarhepatocellularcarcinoma. A study of nine cases and a review of the literature,” The AmericanJournalofSurgery,vol.151,no.4,pp.518–523,1986. D. L. Lildballe, K. Q. T. Nguyen, S. S. Poulsen, H. O. Nielsen, and E. Nexo, “Haptocorrin as marker of disease progression infibrolamellarhepatocellularcarcinoma,”EuropeanJournalof SurgicalOncology,vol.37,no.1,pp.72–79,2011. R. K. G. Do, A. McErlean, C. S. Ang, R. P. Dematteo, and G. K. Abou-Alfa, “CT and MRI of primary and metastatic fibrolamellar carcinoma: A case series of 37 patients,” British JournalofRadiology,vol.87,no.1040,ArticleID20140024,2014. S. Liu, K. Wah Chan, J. Tong, Y. Wang, B. Wang, and L. Qiao, “PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellularcarcinoma:A casereport and a summaryofrecentliterature,”QJM:AnInternationalJournalof Medicine,vol.104,no.6,pp.477–483,2011. C.G.Roth andD.G.Mitchell,“Hepatocellularcarcinomaand otherhepaticmalignancies:MRimaging,”RadiologicClinicsof NorthAmerica,vol.52,no.4,pp.683–707,2014. S. Sethi, N. Tageja, J. Singh et al., “Hyperammonemic encephalopathy:Ararepresentationoffibrolamellarhepatocellularcarcinoma,”TheAmericanJournaloftheMedicalSciences , vol.338,no.6,pp.522–524,2009. C. Berger, P. Dimant, L. Hermida, F. Paulin, M. Pereyra, and M.Tejo,“Hyperammonemicencephalopathyandfibrolamellar hepatocellularcarcinoma,”Medicina(Argentina),vol.72,no.5, pp.425–427,2012. R. A. Sulaiman and T. Geberhiwot, “Fibrolamellar Hepatocellular Carcinoma Mimicking Ornithine Transcarbamylase Deficiency,”inJIMDReportsVolume16,vol.16ofJIMDReports, pp.47–50,SpringerBerlinHeidelberg,Berlin,Heidelberg,2014. C. I. Chapuy, I. Sahai, R. Sharma, A. X. Zhu, and O. N. Kozyreva,“Hyperammonemicencephalopathyassociatedwith fibrolamellar hepatocellular carcinoma: Case report, literature review,andproposedtreatmentalgorithm,”TheOncologist,vol. 21,no.4,pp.514–520,2016. M. N. Mavros, S. C. Mayo, O. Hyder, and T. M. Pawlik, “A systematic review: Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma,” Journal of the AmericanCollegeofSurgeons,vol.215,no.6,pp.820–830,2012. W. T. Kassahun, “Contemporary management of fibrolamellar hepatocellular carcinoma: Diagnosis, treatment, outcome, prognosticfactors,andrecentdevelopments,”WorldJournalof SurgicalOncology,vol.14,no.1,articleno.151,2016. A. D. Pinna, S. Iwatsuki, R. G. Lee et al., “Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation,”Hepatology,vol.26,no.4,pp.877–883,1997. L.G.Atienza,J.Berger,X.Meietal.,“Livertransplantationfor fibrolamellarhepatocellularcarcinoma:Anationalperspective,” JournalofSurgicalOncology,vol.115,no.3,pp.319–323,2017. A.O.Kaseb,M.Shama,I.H.Sahinetal.,“Prognosticindicators and treatmentoutcome in94 casesof fibrolamellar hepatocellularcarcinoma,”Oncology(Switzerland),vol.85,no.4,pp.197– 203,2013. B. Njei, “Fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: Better 5-year survival or artifactualresultofresearchmethodology?”Gut,vol.63,no.9, pp.1374-1375,2014 A. E. Alsina, “Successful Liver Transplantation for HyperammonemicFibrolamellarHepatocellularCarcinoma,”ACGCase ReportsJournal,vol.3,no.4,2016
score 11,388314